• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过亚氨基糖稳定涉及 M51I 氨基酸取代的突变型α-半乳糖苷酶 A 的分子机制。

Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.

机构信息

Department of Analytical Biochemistry, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.

出版信息

Mol Genet Metab. 2011 May;103(1):26-32. doi: 10.1016/j.ymgme.2011.01.013. Epub 2011 Feb 2.

DOI:10.1016/j.ymgme.2011.01.013
PMID:21353612
Abstract

Small molecules including imino sugars are expected to act as chaperones for a mutant α-galactosidase A (GLA), which will be useful for pharmacological chaperone therapy for Fabry disease. However, there is little detailed information about the molecular mechanism. We paid attention to an M51I mutant GLA which had been reported to strongly react to an imino sugar. The predicted structural change caused by this amino acid substitution is very small and located on the surface of the molecule. We produced the mutant enzyme in yeast, and determined its enzymological characteristics. The enzymological parameter values are almost the same as those of the wild-type GLA, although the mutant enzyme is unstable not only under neutral pH conditions but also under acidic ones. Then, we directly examined the effect of imino sugars including 1-deoxygalactonojirimycin and galactostatin bisulfite on the purified mutant enzyme. The imino sugars apparently improved the stability of the mutant enzyme under both neutral and acidic pH conditions. The results of surface plasmon resonance biosensor assaying suggested that the imino sugars retained their binding activity as to the mutant enzyme under both neutral and acidic pH conditions. This information will facilitate improvement of pharmacological chaperone therapy for Fabry disease.

摘要

小分子,包括亚氨基糖,有望作为突变型α-半乳糖苷酶 A(GLA)的伴侣分子,这对于法布里病的药理学伴侣治疗将是非常有用的。然而,关于其分子机制的详细信息却很少。我们关注了一个已报道与亚氨基糖强烈反应的 M51I 突变型 GLA。该氨基酸取代所导致的预测结构变化非常小,并且位于分子表面。我们在酵母中产生了该突变酶,并确定了其酶学特性。尽管突变酶不仅在中性 pH 条件下不稳定,而且在酸性条件下也不稳定,但酶学参数值几乎与野生型 GLA 相同。然后,我们直接检查了包括 1-脱氧半乳糖氮己糖和半乳糖托品双硫酸盐在内的亚氨基糖对纯化的突变酶的影响。亚氨基糖明显改善了突变酶在中性和酸性 pH 条件下的稳定性。表面等离子体共振生物传感器分析的结果表明,在中性和酸性 pH 条件下,亚氨基糖对突变酶仍保持其结合活性。这些信息将有助于改善法布里病的药理学伴侣治疗。

相似文献

1
Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.通过亚氨基糖稳定涉及 M51I 氨基酸取代的突变型α-半乳糖苷酶 A 的分子机制。
Mol Genet Metab. 2011 May;103(1):26-32. doi: 10.1016/j.ymgme.2011.01.013. Epub 2011 Feb 2.
2
Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.亚氨基糖与人α-半乳糖苷酶的分子相互作用:对法布里病中复合物形成机制及药理伴侣作用的深入了解。
Mol Genet Metab. 2009 Apr;96(4):233-8. doi: 10.1016/j.ymgme.2008.12.017. Epub 2009 Jan 31.
3
Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.针对药物伴侣响应的 S529V 突变酸性α-葡萄糖苷酶的生化和结构研究。
J Hum Genet. 2011 Jun;56(6):440-6. doi: 10.1038/jhg.2011.36. Epub 2011 Apr 7.
4
Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism.亚氨基糖与重组人酸性α-葡萄糖苷酶(阿糖苷酶α)相互作用的结合参数及热力学:对复合物形成机制的深入了解
Clin Chim Acta. 2008 May;391(1-2):68-73. doi: 10.1016/j.cca.2008.02.014. Epub 2008 Feb 17.
5
Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.药理学伴侣可纠正由转运功能缺陷变体引起的法布里病中的溶酶体贮积。
Am J Physiol Cell Physiol. 2006 Apr;290(4):C1076-82. doi: 10.1152/ajpcell.00426.2005.
6
Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.法布里病:α-半乳糖苷酶A双重突变及D313Y血浆酶假性缺陷等位基因的特征
Hum Mutat. 2003 Dec;22(6):486-92. doi: 10.1002/humu.10275.
7
A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.一种合成伴侣可纠正蛋白质错误折叠疾病中的运输缺陷和疾病表型。
FASEB J. 2005 Jan;19(1):12-8. doi: 10.1096/fj.04-2375com.
8
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.2,5-二脱氧-2,5-亚氨基-D-甘露醇作为法布里病的新型药理学伴侣。
Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. doi: 10.1016/j.bmc.2010.04.048. Epub 2010 Apr 21.
9
Structural characterization of mutant alpha-galactosidases causing Fabry disease.导致法布里病的突变α-半乳糖苷酶的结构表征。
J Hum Genet. 2008;53(9):812-824. doi: 10.1007/s10038-008-0316-9. Epub 2008 Jul 17.
10
Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.pH值和亚氨基糖药理伴侣对溶酶体糖苷酶结构和稳定性的影响。
Biochemistry. 2009 Jun 9;48(22):4816-27. doi: 10.1021/bi9002265.

引用本文的文献

1
Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.药物重定位治疗法布里病:乙酰水杨酸通过药物伴侣增强溶酶体α-半乳糖苷酶的稳定性。
Int J Mol Sci. 2022 May 4;23(9):5105. doi: 10.3390/ijms23095105.
2
Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.药理学伴侣:一种治疗由不稳定错义突变引起的疾病的方法。
Int J Mol Sci. 2020 Jan 13;21(2):489. doi: 10.3390/ijms21020489.
3
Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
在人溶酶体α-半乳糖苷酶上鉴定出变构结合位点,为法布里病的新型药理伴侣分子开辟了道路。
PLoS One. 2016 Oct 27;11(10):e0165463. doi: 10.1371/journal.pone.0165463. eCollection 2016.
4
High variability of Fabry disease manifestations in an extended Italian family.意大利一个扩展家系中 Fabry 病表现的高度变异性。
Biomed Res Int. 2015;2015:504784. doi: 10.1155/2015/504784. Epub 2015 Apr 22.
5
Carboxyl-terminal truncations alter the activity of the human α-galactosidase A.羧基末端截短会改变人α-半乳糖苷酶A的活性。
PLoS One. 2015 Feb 26;10(2):e0118341. doi: 10.1371/journal.pone.0118341. eCollection 2015.
6
Fabry disease: experience of screening dialysis patients for Fabry disease.法布瑞氏病:对透析患者进行法布瑞氏病筛查的经验。
Clin Exp Nephrol. 2014 Apr;18(2):269-73. doi: 10.1007/s10157-013-0897-2. Epub 2013 Nov 6.
7
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.法布里病的药理学伴侣治疗:从计算机预测到体外试验。
Orphanet J Rare Dis. 2011 Oct 17;6:66. doi: 10.1186/1750-1172-6-66.